Sort   by:  
 Page size 
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
MetabolomicsMetabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells
Genomic instability is one of the hallmarks of cancer. Several chemotherapeutic drugs and radiotherapy induce DNA damage to prevent cancer cell replication. Cells in turn activate different DNA damage response (DDR) pathways to either repair the damage or induce cell death. These DDR pathways also e...
2015-08-01 | MTBLS177 | MetaboLights
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
TranscriptomicsPARP inhibition
PARP inhibition and the effect on Arabidopsis thaliana high light tolerance
ORGANISM(S): Arabidopsis thaliana 
2012-05-01 | E-MTAB-896 | biostudies-arrayexpress
TranscriptomicsPARP-1, H3 and H3K4me3 ChIP-chip from MCF7 cells
We are examining the mechanisms by which the nuclear enzyme PARP-1 regulates gene expression. We performed ChIP-chip for PARP-1, histone H3 and H3K4me3 (lysine 4 trimethylation on histone H3) in MCF7 breast carcinoma cells, and looked at 23550 RefSeq genes to determine binding patterns of these fac...
ORGANISM(S): Homo sapiens 
2010-09-20 | E-GEOD-19619 | biostudies-arrayexpress
TranscriptomicsRNAi of human MCF7 cells knocked down for PARP-1 or PARGs
Poly(ADP-ribose) polymerase-1 (PARP-1) and poly(ADP-ribose) glycohydrolase (PARG) are enzymes that modify target proteins in the nucleus by the addition and removal, respectively, of ADP-ribose polymers. Although a role for PARP-1 in gene regulation has been well established, the role of PARG is le...
ORGANISM(S): Homo sapiens 
2009-10-30 | E-GEOD-12952 | biostudies-arrayexpress
TranscriptomicsExamination of functional interplay between NMNAT-1 (a nuclear NAD+ synthase) and PARP-1 (a nuclear poly(ADP-ribose) polymerase)
NMNAT-1 and PARP-1, two key enzymes in the NAD+ metabolic pathway, localize to the nucleus where integration of their enzymatic activities has the potential to control a variety of nuclear processes. Using a variety of biochemical, molecular, cell-based, and genomic assays, we show that NMNAT-1 and...
ORGANISM(S): Homo sapiens 
2012-02-15 | E-GEOD-35358 | biostudies-arrayexpress
TranscriptomicsIGR_Michels_PARP
Non-small cell lung cancer (NSCLC) is often treated with cisplatin (CDDP). Here, we report that two distinct poly(ADP-ribose) polymerase (PARP) inhibitors exhibited a hyperadditive combination effect with CDDP to kill NSCLC cells. A majority of CDDP-resistant cell lines and clones exhibited constitu...
ORGANISM(S): Homo sapiens 
2013-10-31 | E-MTAB-1353 | biostudies-arrayexpress
ProteomicsChemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets
Poly (ADP-ribose) polymerase 7 (PARP-7) has emerged as a critically important member of a large enzyme family that catalyze ADP-ribosylation in mammalian cells. PARP-7 is a critical regulator of the innate immune response. What remains unclear is the mechanism by which PARP-7 regulates this process,...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020323 | Pride
Chemical genetics Marylation Parp-7 Protein-protein interactions Enzymatic targets 
GenomicsPARP inhibitor augments anti-tumor efficacy of DNMT inhibitor in cholangiocarcinoma
PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor in cholangiocarcinoma
PRJNA1149664 | ENA
Sort   by:  
 Page size